1 2 3 4	The development and validation of a prognostic model to predict relapse in adults with remitted depression in primary care: secondary analysis of pooled individual participant data from multiple studies
5	Andrew S Moriarty <sup>*123</sup> , Lewis W Paton <sup>12</sup> , Kym IE Snell <sup>4,5</sup> , Lucinda Archer <sup>4,5</sup> ,
6	Richard D Riley <sup>4,5</sup> , Joshua EJ Buckman <sup>67</sup> , Carolyn A Chew-Graham <sup>3</sup> , Simon
7	Gilbody <sup>1 2</sup> , Shehzad Ali <sup>2 8</sup> , Stephen Pilling <sup>6</sup> , Nick Meader <sup>9</sup> , Bob Phillips <sup>1 10</sup> , Peter A
8	Coventry <sup>2</sup> , Jaime Delgadillo <sup>11</sup> , David A Richards <sup>1213</sup> , Chris Salisbury <sup>14</sup> , Dean
9	McMillan <sup>12</sup>
10	
11	1. Hull York Medical School, University of York
12	2. Department of Health Sciences, University of York
13	3. School of Medicine, Keele University, Keele, UK
14	4. Institute of Applied Health Research, University of Birmingham, UK
15	5. National Institute for Health and Care Research (NIHR) Birmingham Biomedical
16	Research Centre, UK
17	6. CORE Data Lab, Research Department of Clinical, Educational & Health Psychology,
18	University College London, London, UK.
19	7. iCope - Camden & Islington NHS Talking Therapies for anxiety and depression
20	services - Camden & Islington NHS Foundation Trust, London, UK
21	8. Department of Epidemiology and Biostatistics, Schulich School of Medicine &
22	Dentistry, Western University, London, ON, Canada
23	9. Newcastle University, UK
24	10. Centre for Reviews and Dissemination, University of York, UK
25	11. Department of Psychology, University of Sheffield, UK
26	12. Faculty of Health and Life Sciences, University of Exeter, UK
27	13. Department of Health and Caring Sciences, Western Norway University of Applied
28	Sciences, Inndalsveien 28, 5063 Bergen, Norway
29	14. Centre for Academic Primary Care, University of Bristol, UK

## 30 What is already known on this topic

- 31 Relapse contributes to the morbidity and burden associated with depression and,
- 32 while there is robust research confirming predictors of relapse, individualised risk
- 33 prediction is a challenge.
- 34

## 35 What this study adds

- 36 We found that it is not possible to accurately predict individualised risk of relapse
- 37 using prognostic factors that are routinely collected and available in primary care.
- 38 We found evidence to suggest that relationship status (not being in a relationship) is
- 39 associated with increased risk of relapse and warrants confirmatory prognostic factor
- 40 research.
- 41

# 42 How this study might affect research, practice or policy

- 43 Future prognosis research in this area should focus on exploring the feasibility of
- 44 routinely measuring and documenting additional prognostic factors in primary care
- 45 (for example, adverse childhood events, relationship status and social support) and
- 46 including these in prognostic models. Until we can more accurately identify
- 47 individuals at increased risk of relapse, commonly used acute-phase treatments
- 48 could be optimised to better prepare for and mitigate the risk of relapse and there is
- 49 a need for brief, scalable relapse prevention interventions that could be provided
- 50 more widely.
- 51
- 52 Key words: Relapse; Recurrence; Depression; Prognosis

## 53 ABSTRACT

54

# 55 Background

56 Relapse of depression is common and contributes to the overall associated morbidity

57 and burden. We lack evidence-based tools to estimate an individual's risk of relapse

after treatment in primary care, which may help us more effectively target relapse

- 59 prevention.
- 60

# 61 **Objective**

Develop and validate a prognostic model to predict risk of relapse of depression inprimary care.

64

# 65 Methods

- 66 Multilevel logistic regression models were developed, using individual participant
- 67 data from seven primary care-based studies (n=1244), to predict relapse of

68 depression. The model was internally validated using bootstrapping and

69 generalisability was explored using internal-external cross-validation.

70

# 71 Findings

- 72 Residual depressive symptoms [Odds ratio (OR): 1.13 (95% CI: 1.07-1.20), p<0.001]
- and baseline depression severity [OR: 1.07 (1.04-1.11), p<0.001] were associated
- vith relapse. The validated model had low discrimination [C-statistic 0.60 (0.55-
- 0.65)] and miscalibration concerns [calibration slope 0.81 (0.31-1.31)]. On secondary
- analysis, being in a relationship was associated with reduced risk of relapse [OR:
- 0.43 (0.28-0.67), p<0.001]; this remained statistically significant after correction for
- 78 multiple significance testing.
- 79

# 80 Conclusions

- 81 We cannot currently predict risk of depression relapse with sufficient accuracy in a
- 82 primary care setting, using routinely recorded measures. Relationship status
- 83 warrants further research to explore its role as a prognostic factor for relapse.
- 84

# 85 Clinical implications

- 86 Until we can accurately stratify patients according to risk of relapse, a universal
- 87 approach to relapse prevention may be most beneficial, either during acute phase
- treatment or post-remission. Where possible, this could be guided by the presence
- 89 or absence of known prognostic factors (e.g. residual depressive symptoms) and
- 90 targeted towards these.

#### 91 **1. BACKGROUND**

Depression is the leading cause of disability worldwide(1); the vast majority of adults seeking treatment for depression are managed in primary care(2). Relapse is common, with around half of people experiencing a relapse within one year of reaching remission(3). This high relapse rate contributes to the overall morbidity and burden associated with depression(4).

97

98 An ability to predict an individual patient's risk of relapse after an episode of 99 depression might assist clinicians in targeting relapse prevention interventions 100 toward those at greatest risk. Well-established prognostic factors associated with 101 increased risk of relapse are: residual depressive symptoms; previous depressive 102 episodes; childhood maltreatment; comorbid anxiety; neuroticism; younger age of 103 first onset, and rumination(5). While the presence or absence of these prognostic 104 factors can help refine estimates of overall prognosis to particular sub-groups, they 105 do not effectively aid risk-stratification at the individual level. Sub-grouping methods 106 have been used to predict average risk of relapse for groups of people with different 107 combinations (or profiles) of prognostic factors(6). However, individualised outcome 108 prediction is best shaped using multiple prognostic factors in combination, in the 109 form of multivariable prognostic models(7).

110

111 A systematic review of prognostic models, undertaken by our group, identified 112 twelve studies of relapse prediction models(8). The majority were at high overall risk 113 of bias (the most significant limitations being inadequate sample size, inappropriate 114 handling of missing data, and calibration or discrimination not reported). The 115 developed models either demonstrated insufficient predictive performance on 116 reported validation by the study authors, or they could not be feasibly implemented in 117 a primary care setting due to the large number and type of included predictors. We 118 concluded that we currently lack evidence-based tools to assist clinicians with risk 119 prediction of depressive relapse in any clinical setting, and that new models are 120 required to give accurate risk predictions in primary care settings.

121

122 **2. OBJECTIVE** 

123 To develop and validate a prognostic model, for use in clinical primary care 124 settings, to predict risk of relapse in adults with remitted depression(9).

125

## 126 **3. METHODS**

127 The methods align with the PROGnosis RESearch Strategy (PROGRESS) 128 recommendations(7) and the study is reported according to the Transparent 129 Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis 130 (TRIPOD-Cluster) guidance(10). A Patient Advisory Group (PAG) contributed to this 131 study, including selecting predictors, definition of outcome, target patient population 132 and clinical application. The study was registered prospectively (Clinical Trials.gov: 133 NCT04666662). Further methodological details are available in our protocol 134 paper(9).

135

## 136

## 3.1. Source of data, participants and setting

137 We formed the "PREDICTR" dataset from combined individual participant 138 data (IPD) from UK primary care-based studies(9), identified through a literature 139 search and a review of the NIHR trials registry. Authors were asked to share data if 140 studies included adult patients (18 years and over) with depression, measured using 141 the Patient Health Questionnaire (PHQ-9) at a minimum of three time-points (to 142 identify depression, remission, relapse/no relapse). We excluded studies in patient 143 groups with significant psychiatric comorbidity and feasibility studies. The 144 PREDICTR dataset is derived from all arms (control and intervention) of six RCTs of 145 primary care-based interventions for depression (CADET, CASPER Plus, COBRA, 146 Healthlines Depression, REEACT, and REEACT-2) and one observational cohort 147 study (WYLOW) (Supplemental Table 1.1, Figure 1.1).

148

## 149

## 3.2. Start-point (remission)

Participants were in remission at the point of prediction. Participants must have had case-level depression at baseline [PHQ-9 score of 10 or more(11)], and (at 4 months after trial baseline): i) a post-treatment PHQ-9 score below the established cut-off of 10 [consistent with clinical recovery(3,12)] and ii) an improvement of  $\geq$ 5 points on the PHQ-9 since depression diagnosis [which aligns with an established reliable change index to identify those with "reliable improvement"(13)].

156			
157	3.3.	End	-point/outcome (relapse)
158		Wed	coded participants as relapsed if they fulfilled the following criteria within
159	6-8 m	nonths	post-remission: i) PHQ-9 score above the diagnostic cut-off (10 or more)
160	and ii	i) ≥5 p	oints greater than their symptom score at the time of remission. This is
161	also d	consist	tent with an established criteria for reliable and clinically significant
162	deter	ioratio	n(13).
163			
164	3.	4.	Predictors
165	W	e iden	tified predictors a priori, following a literature review and consensus
166	withir	n the m	nultidisciplinary research team and the PAG. We included predictors that
167	would	d curre	ently be routinely available in primary care settings at the intended
168	mom	ent of	prediction.
169			
170	3.4.1	. Pred	lictors in primary analysis
171		The	following variables have robust evidence for their role as relapse
172	predi	ctors(5	5,14) and were included in the model:
173	•	Resi	dual depressive symptoms (PHQ-9 score at remission (0-9); continuous
174		varia	ıble);
175	•	Prev	ious episodes of depression (dichotomous predictor (0=no previous
176		episo	odes, 1=one or more previous episodes;
177	•	Com	orbid anxiety (measured using the GAD-7(15) in six of the seven studies
178		and	the Clinic Interview Schedule-Revised (CIS-R)(16) in REEACT (see
179		Supp	plemental Table 1.2). These measures were combined to create a
180		com	posite score (z-score), modelled as a continuous predictor;
181	٠	Base	eline severity of depressive symptoms (continuous predictor; PHQ-9 score
182		at ba	aseline (pre-treatment));
183	•	RCT	Intervention: to control for the presence of interventions within the RCTs,
184		we c	oded the presence or absence of an effective intervention (based on the
185		resu	Its of the RCT) as a dichotomous variable. This predictor was intended to
186		conti	rol for the intervention as part of the model building process only; when
187		maki	ing predictions in real-world primary care this predictor would always be

188 set to zero (i.e., no experimental intervention present).

190	3.4.2. Exploratory predictors
191	These are less well-evidenced predictors of relapse and were included as part
192	of an exploratory secondary analysis: age; gender; ethnicity; relationship status;
193	multimorbidity (two or more long-term physical or mental health conditions, excluding
194	depression and comorbid anxiety); employment status (unemployment being those
195	of working age who do not have a job and are actively seeking one); and current
196	antidepressant use(5,14,17).
197	
198	3.5. Sample size
199	We used the pmsampsize package (18) to calculate the required minimum
200	sample size of 722, with 145 events (see protocol for details(9)); our actual sample
201	size (n=1244; 261 events) exceeded this.
202	
203	3.6. Statistical analysis methods
204	
205	3.6.1. Data pre-processing
206	Anonymised data were transferred and stored securely and harmonised in
207	line with the pre-specified harmonisation procedure (Supplemental Table 1.3).
208	
209	3.6.2. Data integrity checks (risk of bias)
210	Data were summarised and checked against publications for key features
211	such as number of participants (total and in each study arm), demographics, primary
212	outcomes of study, relapse rates and missing data. Validity of data values were
213	checked on data inspection and irregularities clarified through communication with
214	the original authors. Risk of bias assessment was undertaken using the participants,
215	predictors and outcome domains of PROBAST(19).
216	
217	3.6.3. Missing data
218	Missing data were handled using multiple imputation with chained equations
219	(MICE), under a missing at random assumption(20). Missing values were imputed
220	based on the values of other predictors and the outcome, using linear models for
221	continuous predictors (residual symptoms, severity, comorbid anxiety) and logistic

189

222 models for binary predictors [number of previous episodes, RCT Intervention, 223 outcome (relapse/no relapse)]. Imputation was undertaken for each study separately, 224 preserving the clustering of participants within studies and any between-study 225 heterogeneity in predictor effects and outcome prevalence. Each imputed dataset 226 was then analysed separately using the same statistical methods, and the estimates 227 were combined using Rubin's rules, to produce an overall estimate and measure of 228 uncertainty of each regression coefficient and model performance measures(10). We 229 used thirty imputations, based on the maximum percentage of participants with one 230 or more missing values across all individual studies(20).

231

232 **3.6.4.** Model development (primary analysis)

233 Multilevel multivariable logistic regression models were built to model the 234 relationship of the predictors with the binary outcome (relapse/no relapse), forcing in 235 all predictors. Model parameters were estimated via unpenalized maximum 236 likelihood estimation, and then penalised post-estimation using a uniform shrinkage 237 factor. The modelling preserved the clustering of participants within studies, with a 238 random effect on the intercept, a random intervention effect, and allowing for 239 between-study correlation in these effects. We explored non-linear relationships in 240the continuous variables using multivariable fractional polynomials (MFPs)(7). 241 Predictive performance statistics (C-statistic for discrimination; calibration slope and 242 calibration-in-the-large) were calculated for the final developed model, first within 243 each cluster in turn and then pooled using random effects meta-analysis to 244 summarise the model's performance across clusters with estimates of the pooled 245 average and 95% confidence intervals. Prediction intervals were constructed to 246 estimate the model's likely performance in new but similar settings(10).Calibration 247 was also assessed visually by producing calibration plots with smooth calibration 248 curves.

249

250 3.6.5. Model validation

The optimism of the developed model was measured using non-parametric bootstrapping. One hundred bootstrap samples (each stratified by study) were produced from the original dataset. Within each bootstrap sample, the same modelling procedures were used as for model development. The model estimated

using each bootstrap sample was then applied in both the same bootstrap sample
('apparent performance') and in the original (imputed) dataset ('test performance').
Each time, average performance measures were calculated by pooling within-study

258 statistics using meta-analysis, as above.

259

260 Optimism was calculated as the difference between apparent and test 261 performance; this process was repeated one hundred times and the average 262 difference between the bootstrap (apparent) and test performance for each 263 performance statistic provided the estimate of overall optimism for that statistic. 264 Optimism-adjusted performance statistics (C-statistic, calibration slope and 265 calibration-in-the-large) were subsequently derived. The uniform shrinkage factor (in 266 this study, the optimism-adjusted calibration slope) was applied to all of the original 267 estimated beta coefficients (to shrink them toward zero to address overfitting) to

268 produce a penalised logistic regression model. Finally, the intercept was re-

269 estimated (whilst constraining the penalised predictor effects at their shrunken value)

to ensure overall calibration was maintained. This formed the final model.

271 Generalisability of the model and between-study heterogeneity in model

272 performance was assessed using internal-external cross-validation (IECV)(21) (see

273 Supplemental Materials 4 for procedure).

274

275 **3.6.6.** Sensitivity analysis

To understand the impact of including a composite measure of comorbid anxiety calculated from both GAD-7 and CIS-R, a sensitivity analysis was performed measuring predictive performance statistics when omitting REEACT and using only GAD-7 as the measure of comorbid anxiety, rather than a z-score.

280

281 3.6.7. Secondary (exploratory) analyses

Univariable analyses were performed to evaluate the unadjusted association between each predictor variable and the outcome variable. Where univariable analysis found statistically significant associations (after accounting for multiple significance testing), the model was refit using all of the original included predictors plus the additional exploratory predictor, to explore the impact on model predictive performance (using only studies in which the exploratory predictor was available).

288

# 289 **3.7.** Ethics approval

The University of York's Health Sciences Research Governance Committee confirmed that this study was exempt from full ethical approval as it entailed the secondary analysis of anonymised data from studies that had already received ethical approval.

294

# 295 **4. RESULTS**

# 2964.1.Summary of data

Table 1 presents the descriptive statistics for the IPD. Supplemental Table 2.1 summarises the missing data. Risk of bias and concerns around applicability were low (Supplemental Table 2.4).

300

301 [Table 1]

Variable	Study										
	CADET	CASPER Plus	COBRA	Healthlines Depression	REEACT	REEACT- 2	WYLOW	Combined PREDICTR IPD dataset			
Total number included in analysis (remission)	158	101	169	110	221	159	326	1244			
Number relapsed at 6-8 months (%)	32 (20)	28 (27.7)	19 (11.2)	24 (21.8)	34 (15.4)	17 (10.7)	107 (32.8)	261 (21)			
Number with one or more previous episodes of depression (%)	112 (70.8)	82 (81.9)	104 (61.5)	89 (80.9)	154 (69.7)	159 (100)	124 (38)	824 (66.2)			
Mean PHQ-9 at	17.35	15.33	17.27	16	15.96	15.77	15.67	16.17			
baseline (SD)	(4.20)	(3.39)	(4.05) 4.08	(3.70)	(3.92)	(3.54)	(4.17) 3.52	(3.98)			
Mean PHQ-9 at remission (SD)	4.70 (2.69)	5.19 (2.50)	4.08 (2.56)	5.97 (2.30)	4.50 (2.61)	4.53 (2.62)	(2.31)	4.40 (2.60)			
Mean GAD-7 (SD)	12.52 (4.83)	8.25 (4.85)	12.41 (4.96)	11.80 (4.44)	GAD-7 not used in REEACT (CIS- R anxiety measure**)	12.97 (4.44)	13.62 (4.63)	12.43 (4.92)			
Mean age (SD)	43.2 (12.9)	71.8 (5.16)	45.3 (13.9)	Not applicable (age is categorical*)	40.3 (13.1)	43.3 (14.7)	41.7 (13.8)	45.1 (15.63)			

Gender:	113	65	100	80	148	102	190	798
Number	(71.5)	(64.3)	(59.2)	(72.7)	(67)	(64.2)	(58.3)	(64.1)
Female (%)								
Ethnicity*:	137	100	165	107	216	154	292	1171
Number White	(86.7)	(99)	(97.6)	(97.2)	(97.7)	(97.5)	(94.2)	(95.4)
(%)								
Employment*:	133	Not	132	105	213	149	214	946
Number	(82.8)	collected	(78.1)	(95.4)	(96.3)	(93.7)	(65.6)	(82.9)
Employed (%)								
Relationship	69	Not	106	Not	140	93	Not	408
status*:	(43.7)	collected	(62.7)	collected	(75.7)	(58.9)	collected	(60.9)
Number In a								
relationship (%)								
Multimorbidity*:	88	86	96	Not	Not collected	Not	87	357
Number with	(55.7)	(85.1)	(56.8)	collected		collected	(29.7)	(49.5)
multimorbidity								
(%)								
Current	113	34	128	98	Not collected	55	130	558
antidepressant	(71.5)	(41)	(75.7)	(90.7)		(41.4)	(40.2)	(57.3)
use: Number								
on								
antidepressants								
at remission								
(%)								

303 \*See Supplemental Table 2.2 for further detail on categorical predictors

304 \*\*See Supplemental Table 2.3 for summary statistics for CIS-R anxiety subscale in REEACT

## 305 **4.2.** Univariable analysis

- 306 Table 2 presents the results from univariable multilevel models. Residual
- 307 symptoms [OR: 1.13 (1.07-1.20)] and severity [OR: 1.07 (1.04-1.11)] were
- 308 statistically significantly associated with relapse; number of previous episodes and
- 309 comorbid anxiety were not.
- 310
- 311 [Table 2]

	Univa	ariable an	alysis*	Primary analysis** (multivariable) Seven studies (n=1244)		Secondary analysis** (multivariable) Four studies (n=707)****	
Predictor	Unadjusted odds ratio (95% CI)	p- value	Number of participants (N)	Regression beta coefficient (95% CI)***	p-value	Regression beta coefficient (95% CI)	p-value
Predictors in primary a	analysis		L.		1		1
Number of previous episodes	1.19 (0.84 to 1.72)	0.319	1117	0.13 (-0.24 to 0.50)	0.500	-0.15 (-0.66 to 0.37)	0.582
Residual symptoms	1.13 (1.07 to 1.20)	<0.001	1244	-2.11 (-3.07 to -1.14)	<0.001	0.07 (-0.01 0.15)	0.081
Baseline severity of depressive symptoms	1.07 (1.04 to 1.11)	<0.001	1244	0.09 (0.04 to 0.13)	<0.001	0.07 (0.01 to 0.13)	0.020
Comorbid anxiety (z- score)	1.04 (0.90 to 1.20)	0.589	1239	-0.13 (-0.30 to 0.03)	0.936	-0.12 (-0.37 to 0.14)	0.363
RCT intervention	0.99 (0.60 to 1.66)	0.981	1244	0.03 (-0.59 to 0.65)	0.936	-0.40 (-0.84 to 0.04)	0.076
Predictors in seconda	ry analysis				1	1	1
Relationship status (in a relationship)	0.43 (0.28 to 0.67)	<0.001	670			-0.79 (-1.23 to -0.34)	0.001
Comorbid anxiety (GAD-7)	1.00 (0.97 to 1.03)	0.943	1019				
Gender (female)	0.87 (0.62 to 1.10)	0.196	1244				
Ethnicity (white)	1.59	0.138	1227				

## Table 2: Univariable and multivariable associations between outcome and predictors (primary and secondary analysis)

		(0.86 to		
		2.93)		
Age (continuous)		1.01	0.198	1133
<b>J</b> <sup>-</sup> (	- /	(1.00 to		
		1.02)		
Age –	<40	Reference c	ategory	1243
				1245
categorical	40-	1.16	0.433	
(years old)	49	(0.80 to		
		1.68)		
	50-	1.31	0.180	
	59	(0.88 to		
		1.95)		
	60-	0.85	0.543	
	69	(0.51 to		
		1.43)		
	70+	1.93	0.037	
		(1.04 to		
		<b>`</b> 3.59)		
Employment		0.76	0.161	1141
(employed)		(0.52 to		
(0		1.11)		
Multimorbidity		1.31	0.158	721
waitmorbialty		(0.90 to	0.100	121
		1.90)		
Current entider	rocont	0.97	0.853	974
Current antidep	Jessani		0.000	974
medication		(0.70 to		
		1.35)		

\* Univariable associations (unadjusted) between predictors and relapse within 6-8 months, after accounting for clustering by study

314 \*\*Beta coefficients before shrinkage (predictors adjusted for other variables in column)

315 \*\*\* Intercept (baseline risk): -1.55 (95% CI: -2.12 to -1.00); Standard deviation of random effect on intercept: 0.43 (95% CI: 0.14 to 1.38); Standard

316 deviation of random effect on slope (RCT Intervention): 0.49 (95% CI: 0.11 to 2.16); Correlation between random effects: -0.23 (-0.93 to 0.84)

317 \*\*\*\*Secondary analysis included only studies with relationship status available (n=707)

# **4.3. Model development and apparent predictive performance**

- Table 2 presents the results of multivariable, multilevel logistic regression
- 320 analysis for the primary analysis. The developed model, prior to shrinkage, had a
- 321 pooled apparent performance of: C-statistic 0.62 (95% CI: 0.57-0.67), calibration
- 322 slope of 0.95 (95% CI: 0.54-1.36), and calibration-in-the-large of 0.03 (95% CI: -0.49-
- 323 0.54). See Supplemental Materials 3 for within-study performance statistics
- 324

# 325 **4.4.** Internal validation, shrinkage and final equation

- 326 Optimism-adjusted performance statistics, after bootstrapping, were: C-statistic
- 0.60, calibration slope 0.81, and calibration-in-the-large 0.03. The final model (Table
- 328 3) was produced by multiplying the original beta regression coefficients (from Table
- 2) by 0.81 (the optimism-adjusted calibration slope), and re-estimating the intercept
- 330 to ensure calibration-in-the-large.
- 331

332 [Table 3]

	Pr	imary analysis	Secondary analysis (exploring relationship status as a predictor)		
Measure of predictive				Without relationship status	With relationship status
performance*	Development (apparent performance)	Internal validation (optimism- adjusted performance)	Internal- external cross validation	Apparent performance	Apparent performance
Number of	1244	1244	1244	707	707
participants	(7)	(7)	(7)	(4)	(4)
(number of					
clusters)					
C-statistic	0.62	0.60	0.60	0.60	0.63
(95% CI*)	(0.57 to 0.67)		(0.55 to	(0.54 to	(0.57 to
			0.65	0.66)	0.70)
Calibration	0.95	0.81	0.81	0.94	0.96
slope	(0.53 to 1.36)		(0.31 to	(0.37 to	(0.56 to
(95% CI*)			1.31)	1.51)	1.36)
Calibration-	0.03	0.03	0.00	0.01	0.01
in-the-large	(-0.49 to		(-0.61 to	(-0.25 to	(-0.20 to
(95% CI*)	0.54)		0.61)	0.27)	0.23)
		1		1	1

## **Table 3:** Summary of model's predictive performance for primary, sensitivity and secondary analyses

\*Pooled predictive performance across studies (within-study performance statistics all available in Supplemental Materials); 95% CI presented,

335 where applicable (not for optimism-adjusted statistics)

336 Final shrunken model: Intercept (baseline risk): -1.49; Shrunken beta coefficients: Number of previous episodes: 0.11, Residual symptoms: -

337 1.71; Severity: 0.07; Comorbid anxiety: -0.11; RCT Intervention: 0.02

338 To calculate the risk of relapse within 6-8 months, using this model, one would use the following formula: exp(person's risk score) ÷ [1 +

339 exp(person's risk score)]

340 Where person's risk score (linear predictor) = -1.49 + 0.11 (Number of previous episodes<sup>1</sup>) – 1.71 (Residual symptoms<sup>2</sup>) + 0.07 (Severity<sup>3</sup>) –

341 0.11 (comorbid anxiety<sup>4</sup>) + 0.02 (RCT Intervention<sup>5</sup>)

<sup>&</sup>lt;sup>1</sup> No previous episodes = 0; One or more previous episodes = 1

<sup>&</sup>lt;sup>2</sup> X<sup>^</sup> -0.5 - 0.43 (where X = (residual\_symptoms+1)) - this is the adjustment for non-linear transformation and mean-centring

<sup>&</sup>lt;sup>3</sup> Severity – 16.17

<sup>&</sup>lt;sup>4</sup> Comorbid\_anx\_zscore + 0.118

<sup>&</sup>lt;sup>5</sup> This would be zero when applied in clinical practice, outside the context of an RCT

#### 4.5. 342 Internal-external cross-validation

343 Generalisability of the model was assessed using IECV(21). Calibration plots 344 were compared for each validation in each of the different studies (Figure 1). These 345 demonstrate inadequate calibration in most studies and significant heterogeneity in predictive performance across clusters. For example, WYLOW study shows severe 346 347 miscalibration, with estimated risks generally too low, whereas in the COBRA study 348 estimated risks are generally too high. In some studies, calibration was generally 349 excellent (e.g., Healthlines Depression)

350

351 [Figure 1: Calibration plots for internal-external cross-validation within each study]

#### **4.6.** Sensitivity analysis

We removed REEACT and repeated the modelling process on the remaining six studies, to assess the impact of using z-scores to model comorbid anxiety. This did not change the study conclusions (see Supplemental Material 5 for analysis).

356

#### 357 **4.7.** Secondary analysis

358 On univariable multilevel logistic analysis, relationship status was a highly 359 statistically significant predictor (after adjusting the significance level to account for 360 multiple significance testing using the Bonferroni correction). To further explore 361 relationship status as a predictor of relapse, we repeated the model development 362 procedures used in the primary analysis for the studies that included relationship 363 status (CADET, COBRA, REEACT, and REEACT-2). We conducted these analyses 364 both with and without the relationship status variable to provide a direct comparison 365 (see Supplemental Material 6). Relationship status remained a statistically significant 366 relapse predictor after adjusting for other prognostic factors (previous episodes, 367 residual symptoms, severity, and comorbid anxiety).

368

#### **5. DISCUSSION**

We developed a model for predicting depression relapse in adults with remitted depression in primary care. Generally, the model had suboptimal predictive performance, with heterogeneous calibration across clusters on IECV and C-statistic below that required for acceptable discrimination. We would not recommend implementation in its current form, though calibration was promising in a subset of studies. Secondary analysis found a statistically significant association between relationship status and relapse.

377

#### **5.1. Findings in the context of the literature**

The performance of this model was in line with the performance measures for previous relapse prediction models(8). Residual symptoms were associated with relapse, which is consistent with existing literature(5,14). Residual symptoms are also associated with a more chronic depression course and poorer psychosocial functioning(22) and, as such, are an established treatment target in depression. The

pre-existing evidence for severity as a prognostic factor for relapse is more equivocal than for residual symptoms(5). Residual symptoms are more likely in people with more severe initial depressive illness(23) and so the presence of residual symptoms may be a mediator of the relationship between baseline severity and relapse.

388

389 The lack of association between previous episodes and relapse in our study is 390 not consistent with the consensus view(5,14). It is possible that this is because it was 391 limited to a binary variable ("no previous episodes" or "one or more previous 392 episodes") in our study. However, the prognostic effect of previous episodes on 393 relapse is known to be strongest when comparing any number of previous episodes 394 to no previous episodes rather than being related to a specific number of previous 395 episodes(5). An alternative explanation may be that previous episodes is most 396 strongly associated with recurrence (which occurs over a longer time period than 397 relapse) and therefore our 6-8 month follow-up was not sufficient to detect this 398 association(5). Comorbid anxiety is recognised as a predictor of relapse(5); in 399 particular, higher levels of anxiety at baseline have been found to predict a shorter 400 time to relapse after treatment(24). In this study, we used anxiety at baseline (when 401 depressed), using GAD-7 and the CIS-R anxiety subscale as measures of comorbid 402 anxiety. It may be that an isolated measure of anxiety symptom severity at a single 403 time-point is a crude measure and less important than knowing an individual's history 404 of comorbid anxiety.

405

406 Marital status (being single) is a risk factor for developing depression(17). A 407 recent study also identified marital status (being single or no longer married) as 408 being associated with a worse prognosis (more depressive symptoms) at 3-4 months 409 (but not beyond 3-4 months)(25). While marital status is not an established predictor 410 of relapse(5,17), our systematic review of prognostic models identified low-quality 411 evidence of an association between relapse and marital status(8). The lack of 412 association between relapse and other exploratory predictors (age, gender, ethnicity, 413 employment status and multimorbidity) is consistent with other findings from the 414 literature(5,14).

415

416 The prognostic factor research cited here is based on longitudinal studies, 417 which examine the predictive value of specific variables based on sample-level

trends. As our systematic review (8) and the current study demonstrate, combining

these well-evidenced relapse predictors to produce individualised predictions of

420 relapse risk remains challenging and calibration remains suboptimal for the purpose

421 of personalised decision-making(7).

422

#### 423 **5.2. Strengths and limitations**

424 This study was conducted according to best practice recommendations for 425 methodology and reporting, with a sufficient sample size to produce precise risk 426 estimates (26). By pre-selecting predictors with a robust, pre-existing evidence base, 427 we aimed to mitigate the risk of overfitting and additional uncertainty associated with 428 more data-driven approaches for predictor selection. While cohort studies and RCTs 429 are recommended sources of data for prognostic model development(7), participants 430 may differ from the general population in important ways and results should be 431 interpreted with this in mind. For example, the majority of participants in this study 432 were white, which limited our ability to explore ethnicity as a predictor. Some 433 potentially useful predictors were not included (e.g., neuroticism, childhood 434 maltreatment and rumination(5)) as they were not coded for in our cohorts (these are 435 also not routinely measured in general practice settings). There was a risk of 436 selection bias given the way studies were selected for inclusion. There was 437 heterogeneity in IPD study populations (e.g., CASPER Plus included older adults), 438 settings and treatment dose. WYLOW followed-up patients after low-intensity CBT 439 whereas interventions in other studies (like COBRA) were more intensive and 440 delivered over a greater number of sessions. While interventions were controlled for 441 in the analysis, this heterogeneity could explain some of the observed miscalibration. 442 Finally, outcomes (remission and relapse) were defined according to PHQ-9 (which 443 is less optimal than diagnostic interview) and over a time-period (6-8 months) 444 necessitated by the IPD data collection points [although one that is aligned with 445 established definitions of relapse(5)].

446

## 447 **5.3. Implications for future research**

The strong statistically significant association between relationship status and relapse in our study warrants further confirmatory prognostic factor research going forwards, to better understand the association between marital/relationship and relapse and how this relates to its better understood association with depression

452 more generally. Further research is needed to better understand whether other 453 relapse predictors can be captured and recorded in an acceptable and valid way by 454 primary care health professionals. For example, we know that routinely asking 455 people about childhood maltreatment is not harmful(27), therefore it may be feasible 456 to explore the use of childhood maltreatment and adversity as part of routine relapse 457 risk assessment in primary care. There have been some efforts to develop clinically 458 useful and valid brief instruments to measure rumination(28), which could be 459 explored in a primary care setting. If there were robust evidence supporting the 460 clinical utility of measuring and documenting additional relapse predictors, health 461 professionals might then adopt this as routine practice. Better data linkage and 462 systems integration across health and wellbeing services may also help address this 463 problem.

464

In this study, we modelled the outcome of relapse as a binary outcome, which enabled us to incorporate criteria for reliable and significant change to define the outcome. It would be informative as part of future work to model the outcome on its continuous scale (i.e., build a linear model that estimates the outcome value, rather than the probability of a binary outcome), with dichotomisation done post-prediction. We focused on outcome occurrence by 6-8 months, but other time-points may be of interest.

472

473 As the IECV in this study demonstrated, there was heterogeneity in the 474 external performance and generalisability of the model was not guaranteed. The 475 studies from which IPD were drawn were generally comparable in terms of baseline 476 demographic variables such as age, gender and ethnicity. Our IECV used the mean 477 intercept and predictor-outcome associations to estimate performance. An 478 alternative approach that could be considered in future work is local recalibration or 479 intercept selection, where similarities in the outcome frequency or baseline 480 characteristics (for example, mean age or proportion female) of a new population of 481 interest is used to guide the intercept when applying the model in a different 482 context(29). If the predictive performance of relapse prediction models can be 483 improved in the future through recalibration or updating, clinical usefulness (using 484 net benefit analysis) must be considered prior to implementation. 485

## 486 6. CLINICAL IMPLICATIONS

487 We cannot currently predict an individual's risk of relapse with a high degree of 488 accuracy, and existing relapse risk prediction models are unlikely to be suitable to 489 guide the provision of relapse prevention. There are different approaches to 490 prevention: universal approaches, which target whole populations; selective 491 approaches, which target higher-risk groups; and indicated approaches, directed at 492 individuals. In the absence of sufficiently accurate relapse risk prediction tools, we 493 argue that a universal approach to relapse prevention of depression in primary care 494 is currently warranted. This is likely to require a systems approach to mitigating the 495 risk of and improving the management of relapse for all patients. This could mean 496 targeting treatment at known prognostic factors (for example, focussing on reducing 497 residual symptoms) or providing interventions as part of treatment during the acute 498 phase of depression that target mechanisms of relapse (for example, prioritising 499 relapse prevention planning)(30). Longer term, brief, inexpensive and scalable 500 relapse prevention interventions are likely to be required for use in primary care. 501

#### 502 FIGURE LEGENDS

503 Figure 1: Calibration plots for internal-external cross-validation within each study

504

## 505 ACKNOWLEDGEMENTS

506 Thank you to the patient advisory group without whose contributions this study would 507 not have been possible: Joanne Castleton, Penney Mayall, Gillian Payne, Sue Penn, 508 and Emma Williams.

509

#### 510 **COMPETING INTERESTS**

- 511 None.
- 512

#### 513 **FUNDING**

514 This report is independent research supported by the National Institute for Health

and Care Research (NIHR Doctoral Research Fellowship, Dr Andrew Moriarty, DRF-

516 2018-11-ST2-044). KIES, RDR and LA are supported by funding from the NIHR

517 Birmingham Biomedical Research Centre (BRC). RDR, SG, DAR and CS are NIHR

518 Senior Investigators. The views expressed in this publication are those of the

- 519 author(s) and not necessarily those of the NHS, the NIHR, or the Department of
- 520 Health and Social Care.
- 521

## 522 AUTHOR CONTRIBUTIONS


- 523 ASM, CCG, SG, SA and DM conceptualised the study and acquired funding. ASM
- 524 led on data curation, study administration and oversight, and wrote the original draft.
- 525 ASM, LWP, KIES, LA, RDR, JEJB and NM contributed to methodology and data
- 526 analysis. SG, JD, DAR and CS were responsible for collecting the data and agreed
- 527 to share these for the purpose of this study. All authors contributed to the pre-
- 528 registered protocol and study plan and all authors contributed to and approved the
- 529 final manuscript.
- 530


## 531 **REFERENCES**

- World Health Organisation. Weekly Epidemiological Report [Internet]. Vol. 30,
   World Health Organiszation. 2017. Available from:
- 534 http://www.who.int/wer/2016/wer9130.pdf?ua=1
- 535 2. Ferenchick EK, Ramanuj P, Pincus HA. Depression in primary care: part 1-536 screening and diagnosis. BMJ. 2019;365:I794.
- Ali S, Rhodes L, Moreea O, McMillan D, Gilbody S, Leach C, et al. How
   durable is the effect of low intensity CBT for depression and anxiety?
   Remission and relapse in a longitudinal cohort study. Behaviour Research and
   Therapy [Internet]. 2017;94:1–8. Available from:
- 541 http://dx.doi.org/10.1016/j.brat.2017.04.006
- Gauthier G, Mucha L, Shi S, Guerin A. Economic burden of relapse/recurrence in patients with major depressive disorder. J Drug Assess [Internet].
   2019;8(1):97–103. Available from:
- 545 https://doi.org/10.1080/21556660.2019.1612410
- Buckman JEJ, Underwood A, Clarke K, Saunders R, Hollon SD, Fearon P, et
   Risk factors for relapse and recurrence of depression in adults and how
   they operate: A four-phase systematic review and meta-synthesis. Clin
   Psychol Rev. 2018;64(July 2017):13–38.
- 550 6. Saunders R, Cohen ZD, Ambler G, Derubeis RJ, Wiles N, Kessler D, et al. A
  551 Patient Stratification Approach to Identifying the Likelihood of Continued
  552 Chronic Depression and Relapse Following Treatment for Depression. J Pers
  553 Med. 2021 Dec 1;11(12).
- 7. Riley RD, van der Windt D, P C, Moons K. Prognosis Research in Healthcare:
   555 Concepts, Methods, and Impact. First edit. Oxford University Press.; 2019.
- Moriarty AS, Meader N, Snell KIE, Riley RD, Paton LW, Dawson S, et al.
   Predicting relapse or recurrence of depression: Systematic review of prognostic models. British Journal of Psychiatry. Cambridge University Press; 2022.
- 5609.Moriarty AS, Paton LW, Snell KIE, Riley RD, Buckman JEJ, Gilbody S, et al.561The development and validation of a prognostic model to PREDICT Relapse of


562		depression in adult patients in primary care: protocol for the PREDICTR study.
563		Diagn Progn Res. 2021 Dec;5(1).
564	10.	Debray TPA, Collins GS, Riley RD, Snell KIE, Van Calster B, Reitsma JB, et
565		al. Transparent reporting of multivariable prediction models developed or
566		validated using clustered data (TRIPOD-Cluster): explanation and elaboration.
567		BMJ [Internet]. 2023 Feb 7;e071058. Available from:
568		https://www.bmj.com/lookup/doi/10.1136/bmj-2022-071058
569	11.	Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a brief
570		depression severity measure. J Gen Intern Med. 2001;16(9):606–13.
571	12.	Clark DM, Layard R, Smithies R, Richards DA, Suckling R, Wright B.
572		Improving access to psychological therapy: Initial evaluation of two UK
573		demonstration sites. Behaviour Research and Therapy. 2009 Nov;47(11):910-
574		20.
575	13.	McMillan D, Gilbody S, Richards D. Defining successful treatment outcome in
576		depression using the PHQ-9: A comparison of methods. J Affect Disord
577		[Internet]. 2010;127(1–3):122–9. Available from:
578		http://dx.doi.org/10.1016/j.jad.2010.04.030
579	14.	Wojnarowski C, Firth N, Finegan M, Delgadillo J. Predictors of depression
580		relapse and recurrence after cognitive behavioural therapy: a systematic
581		review and meta-analysis. Behavioural and Cognitive Psychotherapy [Internet].
582		2019 Sep 21 [cited 2020 Mar 22];47(5):514–29. Available from:
583		https://www.cambridge.org/core/product/identifier/S1352465819000080/type/jo
584		urnal_article
585	15.	Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing
586		generalized anxiety disorder: The GAD-7. Arch Intern Med.
587		2006;166(10):1092–7.
588	16.	Lewis G, Pelosi AJ, Araya R, Dunn G. Measuring psychiatric disorder in the
589		community: A standardized assessment for use by lay interviewers. Psychol
590		Med. 1992;22(2):465–86.
591	17.	Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev.
592		2007;27(8):959–85.
593	18.	Ensor J. PMSAMPSIZE: Stata module to calculate the minimum sample size
594		required for developing a multivariable prediction model. Statistical Software
595		Components S458569, Boston College Department of Economics; 2018.
596	19.	Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, et al.
597		PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction
598		Model Studies. Ann Intern Med [Internet]. 2019;170(1):51. Available from:
599		http://annals.org/article.aspx?doi=10.7326/M18-1376
600	20.	White IR, Royston P, Wood AM. Multiple imputation using chained equations:
601		Issues and guidance for practice. Stat Med. 2011;30(4):377–99.
602	21.	Takada T, Nijman S, Denaxas S, Snell KIE, Uijl A, Nguyen TL, et al. Internal-
603		external cross-validation helped to evaluate the generalizability of prediction
604		models in large clustered datasets. J Clin Epidemiol [Internet]. 2021;137:83-
605	00	91. Available from: https://doi.org/10.1016/j.jclinepi.2021.03.025
606	22.	Kennedy N, Foy K. The Impact of Residual Symptoms on Outcome of Major
607	00	Depression. Curr Psychiatry Rep. 2005;7:441–6.
608	23.	Paykel E, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual
609		symptoms after partial remission: An important outcome in depression.
610		Psychol Med. 1995;25(6):1171–80.

- Forand NR, Derubeis RJ. Pretreatment anxiety predicts patterns of change in cognitive behavioral therapy and medications for depression. J Consult Clin Psychol. 2013;81(5):774–82.
- Buckman JEJ, Saunders R, Stott J, Arundell LL, O'Driscoll C, Davies MR, et
  al. Role of age, gender and marital status in prognosis for adults with
  depression: An individual patient data meta-analysis. Epidemiol Psychiatr Sci.
  2021 Jun 4:30:e42.
- 618 26. Riley RD, Ensor J, Snell KIE, Harrell FE, Martin GP, Reitsma JB, et al.
  619 Calculating the sample size required for developing a clinical prediction model.
  620 BMJ [Internet]. 2020 Mar 18;m441. Available from:
  621 http://www.bmj.com/lookup/doi/10.1136/bmj.m441
- Becker-Blease KA, Freyd JJ. Research participants telling the truth about their
   lives: The ethics of asking and not asking about abuse. American
   Psychologist. 2006 Apr;61(3):218–26.
- Marchetti I, Mor N, Chiorri C, Koster EHW. The brief state rumination inventory
  (BSRI): Validation and psychometric evaluation. Cognit Ther Res. 2018 Feb
  26;42(4):447–60.
- Debray TPA, Moons KGM, Ahmed I, Koffijberg H, Riley RD. A framework for
  developing, implementing, and evaluating clinical prediction models in an
  individual participant data meta-analysis. Stat Med. 2013 Aug 15;32(18):3158–
  80.
- 30. Bockting CL, Hollon SD, Jarrett RB, Kuyken W, Dobson K. A lifetime approach
  to major depressive disorder: The contributions of psychological interventions
  in preventing relapse and recurrence. Clin Psychol Rev [Internet]. 2015;41:16–
- 635 26. Available from: http://dx.doi.org/10.1016/j.cpr.2015.02.003











4) Healthlines Depression



5) REEACT 1 - E:O = 1.267 CITL = -0.297 Slope = 0.485 AUC = 0.550 Observed .4 .4 .6 Expected

.8 i

0 .2



7) WYLOW

